Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Andy Pearce, Director of Discovery Partnerships with Academia at GSK joins the scheme as a Drug Discovery and Development Expert

Andy Pearce

The Business Development Team for the Medical Sciences Division has announced the appointment of a new  expert to its Industry Experts in Residence Scheme. Dr Andy Pearce, Director of Discovery Partnerships with Academia at GSK, joined the scheme in October. 

In his role Dr Pearce leads drug discovery projects from target validation through hit-finding and to the delivery of high quality clinical candidates, across broad disease areas, in collaboration with world-leading academic partners. He is a biochemist and cell biologist by training, and received his undergraduate degree and DPhil from the University of Oxford before undertaking postdoctoral studies at the University of Birmingham. Dr Pearce is a Fellow of the Royal Society of Biology, and he occasionally lectures at Oxford and Cambridge Universities and participates in career panels and workshops for scientists.

Dr Pearce said: ‘I am really excited to be taking up the position of Expert in Residence in Drug Discovery and Development. I am looking forward to meeting Oxford colleagues, discussing some of their great science, and contributing whatever I can to help advance Translational Research in Oxford towards medicines to benefit patients’.

The Industry Experts in Residence programme is managed by the MSD Business Development Team and Oxford University Innovation. It aims to give Oxford's research community access to world-leading expertise and advice across multiple sectors. Researchers can arrange meetings with industry experts to discuss their ideas and projects, and attend seminars given by these experts on a wide range of topics.

The scheme currently hosts experts in product design in biomedical engineering, drug discovery, and digital health, and the appointment of Dr Pearce has made his expertise in Drug Discovery and Development available to researchers. Dr Pearce will sit in the Target Discovery Institute (TDI), Nuffield Department of Medicine, NDM Research Building on various dates during 2018/19. If you would like to arrange a meeting please contact charlotte.bell@medsci.ox.ac.uk

Maxine Allen, Head of Business Development and Partnering for the Medical Sciences Division, commented: 'The Industry Experts in Residence scheme is a fantastic opportunity for our researchers to develop translational strategies for their projects, and an innovative way to foster interaction between industry and academia.

'Find out more about the scheme and book an appointment with an expert 

Similar stories

Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology

The contribution of individual features on clinical imaging scans to the performance of the LCP-CNN cancer risk prediction model developed in Oxford was investigated.

Oxford University retains top spot for spinout generation in the UK

Oxford University has been ranked first in the UK for turning academic research into spinout companies, according to a new report published today by data analyst firm Beauhurst.

The glass half full man: Professor Chas Bountra and Oxford's innovative future

Forget the TV clichés about Oxford – all punting and pass the port. The 925-year-old university is full of the most amazing people who are helping and benefiting the world, well beyond the quads and spires, says Professor Chas Bountra, the university’s Pro-Vice-Chancellor for Innovation. After the events of the last two years - and the COVID-19 vaccine [2.5 billion doses delivered and counting] - this most enthusiastic champion of Oxford maintains there can be no doubt, innovation is part and parcel of the historic university’s future. Who knows what is coming next, he says, expectantly.

Exscientia and University of Oxford launch “Xcellomics” program to expedite early-stage academic research and translate novel biology into future drug discovery

Exscientia and the University of Oxford's Target Discovery Institute (TDI) today announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.

Professor Collins awarded Sir Jules Thorn Translational Biomedical Research Award 2021

Professor Sally Collins has been awarded the prestigious and highly competitive Sir Jules Thorn Translational Biomedical Research Award 2021 for further translational development of the OxNNet Toolkit.

Sir Jon Symonds joins Pharmacology as a Visiting Fellow

The Department of Pharmacology is delighted to announce the appointment of Sir Jonathan Symonds CBE, Chair of the Board of GlaxoSmithKline, as a Visiting Fellow. Jon has been Chairman of the Board at GSK since September 2019.